AB
NGM

Amalgamated Bank’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Amalgamated Bank’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,373
Closed -$2K – 3179
2024
Q1 		$2K Sell
1,373
-2,332
-63% -$3.46K ﹤0.01% 2909
2023
Q4 		$3K Sell
3,705
-409
-10% -$359 ﹤0.01% 2976
2023
Q3 		$4K Hold
4,114
– – ﹤0.01% 2991
2023
Q2 		$11K Sell
4,114
-908
-18% -$3.24K ﹤0.01% 2947
2023
Q1 		$20K Sell
5,022
-795
-14% -$3.67K ﹤0.01% 2659
2022
Q4 		$29K Hold
5,817
– – ﹤0.01% 2640
2022
Q3 		$76K Buy
5,817
+96
+2% +$1.45K ﹤0.01% 2277
2022
Q2 		$73K Buy
5,721
+1,788
+45% +$24.8K ﹤0.01% 2309
2022
Q1 		$60K Buy
+3,933
New +$61.3K ﹤0.01% 2387

Amalgamated Bank's NGM Position: Q2 2024 in Review

Amalgamated Bank sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 1,373 shares — an estimated $2K sold.

Amalgamated Bank first reported a position in NGM in Q1 2022 and held it in 9 quarters. The position peaked at $76K in Q3 2022. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.

  • Amalgamated Bank reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Amalgamated Bank sold 1,373 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $2K.
  • Amalgamated Bank first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 9 quarters.
  • Amalgamated Bank's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $76K in Q3 2022.
  • 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Amalgamated Bank's 13F filing for Q2 2024, filed 12 Aug 2024.